PRRT2 and prostate carcinoma: We have demonstrated that PKC may phosphorylate AR at serine 578 and that, in combination with current diagnostic tools, pARS578 protein expression could provide a desperately needed prognostic marker to aid treatment decision-making in prostate cancer patients at diagnosis.